73例乳腺癌MRP、P53、ER、PR蛋白表达及临床意义

Expression of MRP,P53,ER,PR Proteins in 73 Breast Cancers and their Clinical Significance

目的探讨多药耐药相关蛋白(MRP)、P53、雌激素受体(ER)、孕激素受体(PR)蛋白在乳腺癌组织中表达的特性,相关性和临床意义。方法应用SP免疫组织化学法检测73例乳腺癌标本中MRP、P53、ER、PR蛋白的表达,结合临床、病理资料进行回顾性分析。结果 MRP、P53、ER、PR在乳腺癌中的阳性表达率依次为35.6%(26/73)、69.9%(51/73)、60.3%(44/73)和56.2%(41/73),表达与患者年龄、肿瘤大小、腋窝淋巴结转移和组织学分级无显著相关性,MRP与P53之间存在显著正相关性(P<0.05),MPR与ER/PR的表达无显著性相关(P>0.05),而P53与ER/PR的表达显著相关(P<0.05)。结论乳腺癌MRP、P53、ER和PR的表达为乳腺癌的药物治疗提供了客观参考指标,对制定个体化方案和预后有一定帮助。

Objective To assess the characteristic of multidrug resistance related protein（MRP）,P53,estrogen receptor（ER） and progesterone receptor（PR） proteins expression in breast cancer,and analyze their correlation and clinical significance.Methods The SP immunohistochemical technique was used to detect MRP,P53,ER,and PR proteins expression in 73 patients with breast cancer.The relationships with their clinical and pathological data were retrospectively analyzed.Results The expression rate of MRP,P53,ER,and PR proteins was 35.6%（26/73）,69.9%（51/73）,60.3%（44/73）,and 56.2%（41/73）,retrospectively.The expression of four proteins was not significantly correlated with the patient age,the tumor size,the axillary lymph node metastasis,and the history grade（P〉0.05）.The significantly positive correlation was the expression of MRP and P53,ER /PR and P53（P〈0.05）.No correlation was found in MRP and ER/PR（P〉0.05）.Conclusion It is necessary for detecting MRP,P53,and ER/PR expressions in breast cancer to judge clinical prognosis and make personalized therapeutic plan.